PDF(Pubmed)
Abstract：
Background: Lymphomas account for approximately 10% of all cancer cases among the Saudi population. Even when separated, Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) are in the top ten most commonly diagnosed cancers among Saudi men and women. Despite the substantial cost of HL and NHL to public health, the resources to assess their impact are insufficient. This study provides a two-decade detailed assessment of lymphoma incidence trends in the Saudi population. Methods: Analysis of the Saudi Cancer Registry (SCR) data for various incidence metrics from 2001 to 2020 was conducted. Joinpoint regression analysis was further performed to investigate temporal trends globally and by age group, gender, and administrative region. Results: HL cases grew by 174.1%, whereas NHL cases increased by only 80% for that time period. The HL overall Age-Standardized Incidence Rate (ASR) increased by 100% for both genders combined but remained unchanged for NHL. The median age at diagnosis for HL (20-30 years) and NHL (46-57 years) was lower than in many other nations. Our model identified increasing trends for HL with annual percentage changes (APCs) of 2.94% (CI: 2.2-3.7) and 3.67% (CI: 2.6-4.7) for males and females, respectively. The rise was mainly among young groups under 40. On the contrary, the NHL cohort revealed notable declining tendencies. We discovered alarming rates of HL in Saudi Arabia\'s APC (2.23% for males and 3.88% for females) and ASR compared to other Western countries. Overall, the majority of the patients presented with advanced-stage disease at a younger age and with slight male predominance. Conclusions: The overall incidence of lymphoma (especially HL) has been rising among Saudis. Implementation of secondary and tertiary prevention measures, as well as management of modifiable risk factors, is warranted.
摘要：
背景：在沙特人口中，淋巴瘤约占所有癌症病例的10％。即使分开了,霍奇金淋巴瘤（HL）和非霍奇金淋巴瘤（NHL）是沙特男性和女性中最常见的十大癌症。尽管HL和NHL给公共卫生带来了巨大的成本，评估其影响的资源不足。这项研究提供了沙特人口淋巴瘤发病率趋势的二十年详细评估。方法：对2001年至2020年的各种发病率指标的沙特癌症登记（SCR）数据进行分析。进一步进行Joinpoint回归分析，以调查全球和年龄组的时间趋势，性别,和行政区域。结果:HL病例增长了174.1%,而NHL病例在这段时间内仅增加了80%。两种性别的HL总体年龄标准化发病率（ASR）增加了100％，但NHL的发病率保持不变。诊断为HL（20-30岁）和NHL（46-57岁）的中位年龄低于许多其他国家。我们的模型确定了HL的增长趋势，男性和女性的年度变化百分比（APC）为2.94％（CI：2.2-3.7）和3.67％（CI：2.6-4.7），分别。上升主要是在40岁以下的年轻群体中。相反,NHL队列显示显著下降趋势.我们发现，与其他西方国家相比，沙特阿拉伯的APC中HL的发生率惊人（男性为2.23％，女性为3.88％）和ASR。总的来说,大多数患者在年龄较小的时候出现晚期疾病,并且男性占少数.结论：沙特阿拉伯淋巴瘤（尤其是HL）的总体发病率一直在上升。实施二级、三级预防措施,以及可修改风险因素的管理，是有保证的。
